Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Repaglinid, ATC A10BX02

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jan 03, 2028 · 492 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Repaglinid, ATC A10BX02

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No estimated value or guaranteed volume. Revenues depend on actual prescriptions and market share.

Contracts are automatically terminated if a competitive discount contract for Repaglinide is concluded by AOK Bayern or...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Provision of the pharmaceutical product Repaglinide (ATC A10BX02) under non-exclusive discount agreements with AOK Bayern.
  • Contracts are identical and non-negotiable for all participating pharmaceutical companies.
Afficher le résumé complet

This is an open-house model (not a standard procurement) by AOK Bayern for non-exclusive discount agreements on the active substance Repaglinide (ATC A10BX02). All interested pharmaceutical companies that meet the eligibility criteria can enter into identical, non-negotiable contracts. The contract runs from 01.03.2026 to 29.02.2028, with possible termination on one month's notice. No estimated value is provided. The procedure is open to all, with no competitive award criteria. Documentation is available online via DTVP portal.

Risques

No estimated value or guaranteed volume. Revenues depend on actual prescriptions and market share.

Contracts are automatically terminated if a competitive discount contract for Repaglinide is concluded by AOK Bayern or...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible.
  • Eligibility is demonstrated by a signed declaration of reliability.

Administrative

  • Contract must be submitted in two original copies (if paper) or with qualified electronic signature (if electronic).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Repaglinid, ATC A10BX02

Non-exclusive discount agreements for Repaglinide (ATC A10BX02). Contract duration 01.03.2026 - 29.02.2028. Contracts can be concluded any time until 03.01.2028. Submission deadlines: 3rd of each month for start next month, or 10th for paper originals.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Feb 2026 - Feb 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jan 03, 2028

Détails de la procédure

Date de publication
13 Jan 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
26721-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30